Abstract
For the purpose of nationwide surveillance of the antimicrobial susceptibility of bacterial respiratory pathogens collected from patients in Japan, the Japanese Society of Chemotherapy conducted a third year of nationwide surveillance during the period from January to April 2008. A total of 1,097 strains were collected from clinical specimens obtained from well-diagnosed adult patients with respiratory tract infections. Susceptibility testing was evaluable with 987 strains (189 Staphylococcus aureus, 211 Streptococcus pneumoniae, 6 Streptococcus pyogenes, 187 Haemophilus influenzae, 106 Moraxella catarrhalis, 126 Klebsiella pneumoniae, and 162 Pseudomonas aeruginosa). A total of 44 antibacterial agents, including 26 β-lactams (four penicillins, three penicillins in combination with β-lactamase inhibitors, four oral cephems, eight parenteral cephems, one monobactam, five carbapenems, and one penem), three aminoglycosides, four macrolides (including a ketolide), one lincosamide, one tetracycline, two glycopeptides, six fluoroquinolones, and one oxazolidinone were used for the study. Analysis was conducted at the central reference laboratory according to the method recommended by the Clinical and Laboratory Standard Institute (CLSI). The incidence of methicillin-resistant S. aureus (MRSA) was as high as 59.8%, and those of penicillin-intermediate and penicillin-resistant S. pneumoniae (PISP and PRSP) were 35.5 and 11.8%, respectively. Among H. influenzae, 13.9% of them were found to be β-lactamase-non-producing ampicillin (ABPC)-intermediately resistant (BLNAI), 26.7% to be β-lactamase-non-producing ABPC-resistant (BLNAR), and 5.3% to be β-lactamase-producing ABPC-resistant (BLPAR) strains. A high frequency (76.5%) of β-lactamase-producing strains was suspected in Moraxella catarrhalis isolates. Four (3.2%) extended-spectrum β-lactamase-producing K. pneumoniae were found among 126 strains. Four isolates (2.5%) of P. aeruginosa were found to be metallo β-lactamase-producing strains, including three (1.9%) suspected multidrug-resistant strains showing resistance to imipenem, amikacin, and ciprofloxacin. Continual national surveillance of the antimicrobial susceptibility of respiratory pathogens is crucial in order to monitor changing patterns of susceptibility and to be able to update treatment recommendations on a regular basis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 16th informational supplement M100-S16 and M45-P. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. Document M7-A7. Wayne: Clinical and Laboratory Standards Institute; 2006.
Hanaki H, Kubo R, Nakano T, Kurihara M, Sunagawa K. Characterization of HMRZ-86: a novel chromogenic cephalosporin for the detection of extended-spectrum beta-lactamases. J Antimicrob Chemother. 2004;53(5):888–9.
Colodner R, Reznik B, Gal V, Yamazaki H, Hanaki H, Kubo R. Evaluation of a novel kit for the rapid detection of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 2006;25(1):49–51.
Jenkins SG, Farrell DJ, Patel M, Lavin BS. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000–2003: PROTEKT US years 1–3. J Infect. 2005;51(5):355–63.
Barada K, Hanaki H, Ikeda S, Yamaguchi Y, Akama H, Nakae T, Inamatsu T, Sunakawa K. Trends in the gentamicin and arbekacin susceptibility of methicillin-resistant Staphylococcus aureus and the genes encoding aminoglycoside-modifying enzymes. J Infect Chemother. 2007;13(2):74–8.
Mochizuki T, Okamoto N, Yagishita T, Takuhiro K, Mashiko K, Ogawa F, Tosaka N, Kurokawa A, Yamamoto Y. Analysis of antimicrobial drug resistance of Staphylococcus aureus strains by WHONET 5: microbiology laboratory database software. J Nippon Med Sch. 2004;71(5):345–51.
Kamiya H, Kato T, Togashi T, Iwata S, Kurosaki T, Baba S, Masuda S, Sato S, Yoshimura O, Fujii M, Shimada A, Yagi K, Yano H, Sugita R, Fujimaki Y, Komatsu N, Tango T, The Research Group on Streptococcus Pneumoniae Serotypes among Children. Epidemiological survey of pneumococcus serotypes in pediatric patients with acute suppurative otitis media. Kansenshogaku Zasshi. 2007;81(1):59–66. (in Japanese; abstract in English).
Chiba N, Kobayashi R, Hasegawa K, Morozumi M, Nakayama E, Tajima T, Iwata S, Ubukata K, Acute Respiratory Diseases Study Group. Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of Streptococcus pneumoniae isolates from community-acquired pneumonia in children. J Antimicrob Chemother. 2005;56(4):756–60.
James A, Karlowsky JA, Thornsberry C, Critchley IA, Jones ME, Evangelista AT, Noel GJ, Sahm DF. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000–2001 and 2001–2002 TRUST Studies in the United States. Antimicrob Agents Chemother. 2003;47(6):1790–7.
Hasegawa K, Kobayashi R, Takada E, Ono A, Chiba N, Morozumi M, Iwata S, Sunakawa K, Ubukata K. Nationwide surveillance for bacterial meningitis. High prevalence of type b beta-lactamase-non-producing ampicillin-resistant Haemophilus influenzae in meningitis: the situation in Japan where Hib vaccine has not been introduced. J Antimicrob Chemother. 2006;57(6):1077–82.
Yagi T, Kurokawa H, Shibata N, Shibayama K, Arakawa Y. A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett. 2000;184:53–6.
Yamaguchi K, Ishii Y, Iwata M, Watanabe N, Uehara N, Yasujima M, Kasai T, Suwabe A, Yamahata K, Kaku M, Kanemitsu K, Imafuku Y, Nishiyama K, Murakami M, Yomoda S, Taniguchi N, Yamada T, Nomura F, Watanabe M, Kanno H, Aihara M, Maesaki S, Hashikita G, Kondo S, Misawa S, Horiuchi H, Tazawa Y, Nakashima H, Takemura H, Okada M, Yamazaki F, Horii T, Maekawa M, Baba H, Ishigo S, Fujita N, Komori T, Ichiyama S, Iinuma Y, Maeda S, Yamanaka K, Murata Y, Matsuo S, Kohno H, Kinoshita S, Fujita J, Negayama K, Murase M, Miyamoto H, Kusano N, Mihara E, Itaha H, Ono J, Yoshimura H, Yanagihara K, Matsuda J, Saikawa T, Hiramatsu K. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006. Jpn J Antibiot. 2007;60:344–77.
Yamaguchi K, Ohno A, Ishii Y, Tateda K, Iwata M, Kanda M, Akizawa K, Shimizu C, Kon S, Nakamura K, Matsuda K, Tominaga M, Nakagawa T, Sugita A, Ito T, Kato J, Suwabe A, Yamahata K, Kawamura C, Tashiro H, Horiuchi H, Katayama Y, Kondou S, Misawa S, Murata M, Kobayashi Y, Okamoto H, Yamazaki K, Okada M, Haruki K, Kanno H, Aihara M, Maesaki S, Hashikita G, Miyajima E, Sumitomo M, Saito T, Yamane N, Kawashima C, Akiyama T, Ieiri T, Yamamoto Y, Okamoto Y, Okabe H, Moro K, Shigeta M, Yoshida H, Yamashita M, Hida Y, Takubo T, Kusakabe T, Masaki H, Heijyou H, Nakaya H, Kawahara K, Sano R, Matsuo S, Kono H, Yuzuki Y, Ikeda N, Idomuki M, Soma M, Yamamoto G, Kinoshita S, Kawano S, Oka M, Kusano N, Kang D, Ono J, Yasujima M, Miki M, Hayashi M, Okubo S, Toyoshima S, Kaku M, Sekine I, Shiotani J, Horiuchi H, Tazawa Y, Yoneyama A, Kumasaka K, Koike K, Taniguchi N, Ozaki Y, Uchida T, Murakami M, Inuzuka K, Gonda H, Yamaguchi I, fujimoto Y, Iriyama J, Asano Y, Genma H, Maekawa M, Yoshimura H, Nakatani K, Baba H, Ichiyama S, Fujita S, Kuwabara M, Okazaki T, Fujiwara H, Ota H, Nagai A, Fujita J, Negayama K, Sugiura T, Kamioka M, Murase M, Yamane N, Nakasone I, Okayama A, Aoki Y, Kusaba K, Nakashima Y, Miyanohara H, Hiramatsu K, Saikawa T, Yanagihara K, Matsuda J, Kohno S, Mashiba K. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007. Jpn J Antibiot. 2009;62:346–70.
Niki Y, Hanaki H, Matsumoto T, Yagisawa M, Kohno S, Aoki N, Watanabe A, Sato J, Hattori R, Terada M, Koashi N, Kozuki T, Maruo A, Morita K, Ogasawara K, Takahashi Y, Watanabe J, Takeuchi K, Fujimura S, Takeda H, Ikeda H, Sato N, Niitsuma K, Saito M, Koshiba S, Kaneko M, Miki M, Nakanowatari S, Honda Y, Chiba J, Takahashi H, Utagawa M, Kondo T, Kawana A, Konosaki H, Aoki Y, Ueda H, Sugiura H, Ichioka M, Goto H, Kurai D, Okazaki M, Yoshida K, Yoshida T, Tanabe Y, Kobayashi S, Okada M, Tsukada H, Imai Y, Honma Y, Nishikawa K, Yamamoto T, Kawai A, Kashiwabara T, Takesue Y, Wada Y, Nakajima K, Miyara T, Toda H, Mitsuno N, Sugimura H, Yoshioka S, Kurokawa M, Munekawa Y, Nakajima H, Kubo S, Ohta Y, Mikasa K, Maeda K, Kasahara K, Koizumi A, Sano R, Yagi S, Takaya M, Kurokawa Y, Kusano N, Mihara E, Kuwabara M, Fujiue Y, Ishimaru T, Matsubara N, Kawasaki Y, Tokuyasu H, Masui K, Negayama K, Ueda N, Ishimaru M, Nakanishi Y, Fujita M, Honda J, Kadota J, Hiramatsu K, Aoki Y, Nagasawa Z, Suga M, Muranaka H, Yanagihara K, Fujita J, Tateyama M, Sunakawa K, Totsuka K. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2009;15(3):156–67.
Acknowledgments
This investigation was supported by grants from the following pharmaceutical companies (in alphabetical order): Abbott Japan Co., Ltd.; Astellas Pharma Inc.; Banyu Pharmaceutical Co., Ltd.; Bayer Yakuhin, Ltd.; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Company Limited; Dainippon Sumitomo Pharma Co., Ltd.; Glaxo SmithKline K. K.; Kyorin Pharmaceutical Co., Ltd.; Meiji Seika Kaisha, Ltd.; Pfizer Japan Inc.; Sanofi-Aventis K.K., Shionogi & Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Taisho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Company Limited; and Toyama Chemical Co., Ltd. We are grateful to T. Nakae and C. Yanagisawa at the Kitasato Institute (Tokyo, Japan) for their encouragement with the microbiological testing and Y. Suzuki, H. Endo, and Y. Yamaguchi for their technical assistance in this surveillance.
Author information
Authors and Affiliations
Corresponding author
Additional information
The members of The Japanese Society of Chemotherapy (JSC) Surveillance Committee are listed in the Appendix.
Appendix
Appendix
The Japanese Society of Chemotherapy Surveillance Committee
Y. Niki, T. Matsumoto, S. Kohno, N. Aoki, A. Watanabe, J. Sato, R. Hattori, N. Koashi, M. Terada, T. Kozuki, A. Maruo, K. Morita, K. Ogasawara, Y. Takahashi, K. Matsuda, K. Nakanishi, and K. Totsuka
About this article
Cite this article
Niki, Y., Hanaki, H., Matsumoto, T. et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother 17, 510–523 (2011). https://doi.org/10.1007/s10156-011-0214-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10156-011-0214-5